TEST B BANK B FOR B PHARMACOLOGY B CLEAR B AND B SIMPLE- B A B GUIDE B TO B DRUG
B CLASSIFICATIONS B AND B DOSAGEB CALCULATIONS B 3RD B
EDITION B BY B B WATKINS B T B B WITH B DETAILED B QUESTIONS B AND
B VERIFIED B ANSWERS B (FEED B BACK) B ALREADY B GRADED B A+…
,Pharmacology Clear and Simple- A Guide to Drug Classifications and
B B B B B B B B B B
DosageCalculations 3rd Edition Watkins Test Bank
B B B B B B
Chapter B 1. B History B of B Pharmacology
1. A B nurse B working B in B radiology B administers B iodine B to B a B patient B who B
is B having B aBcomputed B tomography B (CT) B scan. B The B nurse B working B on B
the B oncology B unit B administers B chemotherapy B to B patients B who B have B
cancer. B At B the B Public B HealthBDepartment, B a B nurse B administers B a B
measles-mumps-rubella B (MMR) B vaccine B to B a B 14-month-old B child B as B a B
routine B immunization. B Which B branch B of B pharmacology B best B describes B
the B actions B of B all B three B nurses?
A) Pharmacoeconomics
B) Pharmacotherapeutics
C) Pharmacodynamics
D) Pharmacokinetics
Ans: B
Feedback:
Pharmacology B is B the B study B of B the B biologic B effects B of B chemicals. B
Nurses B are B involved B with B clinical B pharmacology B or B
pharmacotherapeutics, B which B is B a B branch B of B pharmacology B that B deals B
with B the B uses B of B drugs B to B treat, B prevent, B and B diagnose B disease. B The B
radiology B nurse B is B administering B a B drug B to B help B diagnose B a B disease. B
The B oncology B nurse B is B administering B a B drug B to B help B treatBa B disease. B
Pharmacoeconomics B includes B any B costs B involved B in B drug B therapy.B
Pharmacodynamics B involves B how B a B drug B affects B the B body B and B
pharmacokinetics B is B how B the B body B acts B on B the B body.
2. A B physician B has B ordered B intramuscular B (IM) B injections B of B morphine, B
a B narcotic, B every B 4 B hours B as B needed B for B pain B in B a B motor B vehicle B
accident B victim. B The B nurse B is B aware B this B drug B has B a B high B abuse B
potential. B Under B whatBcategory B would B morphine B be B classified?
A) Schedule B I
B) Schedule B II
C) Schedule B III
D) Schedule B IV
Ans: B
, Feedback:
Narcotics B with B a B high B abuse B potential B are B classified B as B Schedule B II B
drugs B because B of B severe B dependence B liability. B Schedule B I B drugs B have B
high B abuse B potential B and B no B accepted B medical B use. B Schedule B III B
drugs B have B a B lesser B abuse B potential B than B II B and B an B accepted B medical
B use. B Schedule B IV B drugs B haveB low B abuse B potential B and B limited B
dependence B liability.
3. When B involved B in B phase B III B drug B evaluation B studies, B what B
responsibilitiesBwould B the B nurse B have?
A) Working B with B animals B who B are B given B experimental B drugs
B) Choosing B appropriate B patients B to B be B involved B in B the B drug B study
C) Monitoring B and B observing B patients B closely B for B adverse B effects
D) Conducting B research B to B determine B effectiveness B of B the B drug
Ans: C
Feedback:
Phase B III B studies B involve B use B of B a B drug B in B a B vast B clinical B population
B in B whichB patients B are B asked B to B record B any B symptoms B they B experience
B while B taking B theB drugs. B Nurses B may B be B responsible B for B helping B
collect B and B analyze B the B information B to B be B shared B with B the B Food B and
B Drug B Administration B (FDA) B butB would B not B conduct B research B
independently B because B nurses B do B not B prescribe B medications. B Use B of B
animals B in B drug B testing B is B done B in B the B preclinical B trials. B Select B
patients B who B are B involved B in B phase B II B studies B to B participate B in B
studies B where B the B participants B have B the B disease B the B drug B is B intended B
to B treat. B These B patients B are B monitored B closely B for B drug B action B and B
adverse B effects. B Phase B I B studies B involve B healthy B human B volunteers B
who B are B usually B paid B for B their B participation. B Nurses B may B observe B for B
adverse B effects B and B toxicity.
4. What B concept B is B considered B when B generic B drugs B are B substituted B
for B brandBname B drugs?
A) Bioavailability
B) Critical B concentration
C) Distribution
D) Half-life
Ans: A
Feedback:
, Bioavailability B is B the B portion B of B a B dose B of B a B drug B that B reaches B the B
systemic B circulation B and B is B available B to B act B on B body B cells. B Binders B
used B in B a B generic B drug B may B not B be B the B same B as B those B used B in B the B
brand B name B drug. B Therefore, B the B way B the B body B breaks B down B and B
uses B the B drug B may B differ, B which B may B eliminate B a B generic B drug B
substitution. B Critical B concentration B is B the B amount B ofBa B drug B that B is B
needed B to B cause B a B therapeutic B effect B and B should B not B differ B between B
generic B and B brand B name B medications. B Distribution B is B the B phase B of B
pharmacokinetics, B which B involves B the B movement B of B a B drug B to B the B
bodys B tissues B and B is B the B same B in B generic B and B brand B name B drugs. B A
B drugs B half-life B isB
the B time B it B takes B for B the B amount B of B drug B to B
decrease B to B half B the B peak B level, B which B should B not B change B when B
substituting B a B generic B medication.
5. A B nurse B is B assessing B the B patients B home B medication B use. B After B
listening B to B theBpatient B list B current B medications, B the B nurse B asks B what B
priority B question?
A) Do B you B take B any B generic B medications?
B) Are B any B of B these B medications B orphan B drugs?
C) Are B these B medications B safe B to B take B during B pregnancy?
D) Do B you B take B any B over-the-counter B medications?
Ans: D
Feedback:
It B is B important B for B the B nurse B to B specifically B question B use B of B over-the-
counter B medications B because B patients B may B not B consider B them B
important. B The B patient B is B unlikely B to B know B the B meaning B of B orphan B
drugs B unless B they B too B are B health B care B providers. B Safety B during B
pregnancy, B use B of B a B generic B medication, B or B classification B of B orphan B
drugs B are B things B the B patient B would B be B unable B to B answer B but B could B be
B found B in B reference B books B if B the B nurse B wishes B to B researchB them.
6. After B completing B a B course B on B pharmacology B for B nurses, B what B will B
the B nurseBknow?
A) Everything B necessary B for B safe B and B effective B medication B administration
B) Current B pharmacologic B therapy; B the B nurse B will B not B require B
ongoingBeducation B for B 5 B years.
C) General B drug B information; B the B nurse B can B consult B a B drug B guide B for
B specificB
drug B information.
D) The B drug B actions B that B are B associated B with B each B
classification B ofBmedication
Ans: C
Feedback:
B CLASSIFICATIONS B AND B DOSAGEB CALCULATIONS B 3RD B
EDITION B BY B B WATKINS B T B B WITH B DETAILED B QUESTIONS B AND
B VERIFIED B ANSWERS B (FEED B BACK) B ALREADY B GRADED B A+…
,Pharmacology Clear and Simple- A Guide to Drug Classifications and
B B B B B B B B B B
DosageCalculations 3rd Edition Watkins Test Bank
B B B B B B
Chapter B 1. B History B of B Pharmacology
1. A B nurse B working B in B radiology B administers B iodine B to B a B patient B who B
is B having B aBcomputed B tomography B (CT) B scan. B The B nurse B working B on B
the B oncology B unit B administers B chemotherapy B to B patients B who B have B
cancer. B At B the B Public B HealthBDepartment, B a B nurse B administers B a B
measles-mumps-rubella B (MMR) B vaccine B to B a B 14-month-old B child B as B a B
routine B immunization. B Which B branch B of B pharmacology B best B describes B
the B actions B of B all B three B nurses?
A) Pharmacoeconomics
B) Pharmacotherapeutics
C) Pharmacodynamics
D) Pharmacokinetics
Ans: B
Feedback:
Pharmacology B is B the B study B of B the B biologic B effects B of B chemicals. B
Nurses B are B involved B with B clinical B pharmacology B or B
pharmacotherapeutics, B which B is B a B branch B of B pharmacology B that B deals B
with B the B uses B of B drugs B to B treat, B prevent, B and B diagnose B disease. B The B
radiology B nurse B is B administering B a B drug B to B help B diagnose B a B disease. B
The B oncology B nurse B is B administering B a B drug B to B help B treatBa B disease. B
Pharmacoeconomics B includes B any B costs B involved B in B drug B therapy.B
Pharmacodynamics B involves B how B a B drug B affects B the B body B and B
pharmacokinetics B is B how B the B body B acts B on B the B body.
2. A B physician B has B ordered B intramuscular B (IM) B injections B of B morphine, B
a B narcotic, B every B 4 B hours B as B needed B for B pain B in B a B motor B vehicle B
accident B victim. B The B nurse B is B aware B this B drug B has B a B high B abuse B
potential. B Under B whatBcategory B would B morphine B be B classified?
A) Schedule B I
B) Schedule B II
C) Schedule B III
D) Schedule B IV
Ans: B
, Feedback:
Narcotics B with B a B high B abuse B potential B are B classified B as B Schedule B II B
drugs B because B of B severe B dependence B liability. B Schedule B I B drugs B have B
high B abuse B potential B and B no B accepted B medical B use. B Schedule B III B
drugs B have B a B lesser B abuse B potential B than B II B and B an B accepted B medical
B use. B Schedule B IV B drugs B haveB low B abuse B potential B and B limited B
dependence B liability.
3. When B involved B in B phase B III B drug B evaluation B studies, B what B
responsibilitiesBwould B the B nurse B have?
A) Working B with B animals B who B are B given B experimental B drugs
B) Choosing B appropriate B patients B to B be B involved B in B the B drug B study
C) Monitoring B and B observing B patients B closely B for B adverse B effects
D) Conducting B research B to B determine B effectiveness B of B the B drug
Ans: C
Feedback:
Phase B III B studies B involve B use B of B a B drug B in B a B vast B clinical B population
B in B whichB patients B are B asked B to B record B any B symptoms B they B experience
B while B taking B theB drugs. B Nurses B may B be B responsible B for B helping B
collect B and B analyze B the B information B to B be B shared B with B the B Food B and
B Drug B Administration B (FDA) B butB would B not B conduct B research B
independently B because B nurses B do B not B prescribe B medications. B Use B of B
animals B in B drug B testing B is B done B in B the B preclinical B trials. B Select B
patients B who B are B involved B in B phase B II B studies B to B participate B in B
studies B where B the B participants B have B the B disease B the B drug B is B intended B
to B treat. B These B patients B are B monitored B closely B for B drug B action B and B
adverse B effects. B Phase B I B studies B involve B healthy B human B volunteers B
who B are B usually B paid B for B their B participation. B Nurses B may B observe B for B
adverse B effects B and B toxicity.
4. What B concept B is B considered B when B generic B drugs B are B substituted B
for B brandBname B drugs?
A) Bioavailability
B) Critical B concentration
C) Distribution
D) Half-life
Ans: A
Feedback:
, Bioavailability B is B the B portion B of B a B dose B of B a B drug B that B reaches B the B
systemic B circulation B and B is B available B to B act B on B body B cells. B Binders B
used B in B a B generic B drug B may B not B be B the B same B as B those B used B in B the B
brand B name B drug. B Therefore, B the B way B the B body B breaks B down B and B
uses B the B drug B may B differ, B which B may B eliminate B a B generic B drug B
substitution. B Critical B concentration B is B the B amount B ofBa B drug B that B is B
needed B to B cause B a B therapeutic B effect B and B should B not B differ B between B
generic B and B brand B name B medications. B Distribution B is B the B phase B of B
pharmacokinetics, B which B involves B the B movement B of B a B drug B to B the B
bodys B tissues B and B is B the B same B in B generic B and B brand B name B drugs. B A
B drugs B half-life B isB
the B time B it B takes B for B the B amount B of B drug B to B
decrease B to B half B the B peak B level, B which B should B not B change B when B
substituting B a B generic B medication.
5. A B nurse B is B assessing B the B patients B home B medication B use. B After B
listening B to B theBpatient B list B current B medications, B the B nurse B asks B what B
priority B question?
A) Do B you B take B any B generic B medications?
B) Are B any B of B these B medications B orphan B drugs?
C) Are B these B medications B safe B to B take B during B pregnancy?
D) Do B you B take B any B over-the-counter B medications?
Ans: D
Feedback:
It B is B important B for B the B nurse B to B specifically B question B use B of B over-the-
counter B medications B because B patients B may B not B consider B them B
important. B The B patient B is B unlikely B to B know B the B meaning B of B orphan B
drugs B unless B they B too B are B health B care B providers. B Safety B during B
pregnancy, B use B of B a B generic B medication, B or B classification B of B orphan B
drugs B are B things B the B patient B would B be B unable B to B answer B but B could B be
B found B in B reference B books B if B the B nurse B wishes B to B researchB them.
6. After B completing B a B course B on B pharmacology B for B nurses, B what B will B
the B nurseBknow?
A) Everything B necessary B for B safe B and B effective B medication B administration
B) Current B pharmacologic B therapy; B the B nurse B will B not B require B
ongoingBeducation B for B 5 B years.
C) General B drug B information; B the B nurse B can B consult B a B drug B guide B for
B specificB
drug B information.
D) The B drug B actions B that B are B associated B with B each B
classification B ofBmedication
Ans: C
Feedback: